Nektar Therapeutics (NKTR) Depreciation & Amortization (CF) (2010 - 2026)

Nektar Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $151000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 64.55% year-over-year to $151000.0; the TTM figure through Mar 2026 stood at $685000.0 (down 63.37% YoY), while the FY2025 annual figure was $1.0 million, down 76.63% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $151000.0, down from $190000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $3.7 million in Q1 2022, with the low at $151000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $1.6 million (2024), against an average of $1.5 million.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) gained 5.28% in 2022, then tumbled 79.9% in 2024.
• Nektar Therapeutics' Depreciation & Amortization (CF) stood at $3.2 million in 2022, then tumbled by 48.08% to $1.7 million in 2023, then sank by 79.9% to $332000.0 in 2024, then slumped by 42.77% to $190000.0 in 2025, then slipped by 20.53% to $151000.0 in 2026.
• Business Quant data shows NKTR's Depreciation & Amortization (CF) at $151000.0 in Q1 2026, $190000.0 in Q4 2025, and $163000.0 in Q3 2025.